NNPDF central office received the following update from the National
Institute of Health (NIH) NPC Clinic from Dr. Forbes "Denny" Porter.
were informed today that the FDA has removed the clinical hold on the
hydroxypropyl-β-cyclodextrin trial. We are planning to enroll the first
patient in two weeks. This trial is a major step in trying to determine
if this is a safe and biochemically effective drug for NPC. Our goal is
to use data from this trial to optimize the design of a larger second
trial focused on clinical efficacy. Thank you for your help and support! The TRND Team"